SCHEMBL6686446

SCHEMBL6686446

NC(=O)c1cccc(Cn2c3c(c4cccc(C(=O)O)c42)CCCCC3)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 18/20 1.00
FABP3 P05413 4/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30398078 1.00 FABP4 (1.00) FABP4FABP3
SCHEMBL6692111 0.92 FABP4 (0.86) FABP4FABP3
SCHEMBL6695535 0.89 FABP4 (0.82) FABP4FABP3
SCHEMBL6687926 0.88 FABP4 (1.00) FABP4FABP3
SCHEMBL6691438 0.87 FABP4 (1.00) FABP4FABP3
SCHEMBL6682983 0.86 FABP4 (0.75) FABP4FABP3
SCHEMBL6688400 0.86 FABP4 (0.75) FABP4FABP3
SCHEMBL6685668 0.85 FABP4 (1.00) FABP4FABP3
SCHEMBL6686650 0.85 FABP4 (0.81) FABP4FABP3
SCHEMBL6682302 0.85 FABP4 (0.74) FABP4FABP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116761598-A Antiviral use of FABP4 modulating compounds 新月生物科学 2023-09-15 CN claimed
US-20230255933-A1 ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS CRESCENTA BIOSCIENCES (US) 2023-08-17 US claimed
US-20230241025-A1 ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS CRESCENTA BIOSCIENCES (US) 2023-08-03 US claimed
EP-4175647-A1 ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS Crescenta Biosciences (US) 2023-05-10 EP claimed
WO-2022010951-A1 ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS CRESCENTA BIOSCIENCES (US) 2022-01-13 WO claimed
WO-2004063156-A1 NOVEL INDOLE DERIVATES AS FABP-4 INHIBITORS BIOVITRUM AB (SE) 2004-07-29 WO claimed
US-12138243-B2 Antiviral use of FABP4 modulating compounds CRESCENTA BIOSCIENCES (US) 2024-11-12 US disclosed
CN-116761598-A Antiviral use of FABP4 modulating compounds 新月生物科学 2023-09-15 CN disclosed
US-20230255933-A1 ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS CRESCENTA BIOSCIENCES (US) 2023-08-17 US disclosed
US-20230241025-A1 ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS CRESCENTA BIOSCIENCES (US) 2023-08-03 US disclosed
EP-4175647-A1 ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS Crescenta Biosciences (US) 2023-05-10 EP disclosed
WO-2022010951-A1 ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS CRESCENTA BIOSCIENCES (US) 2022-01-13 WO disclosed
US-20210254056-A1 IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS CAMP4 THERAPEUTICS CORPORATION 2021-08-19 US disclosed
US-9598365-B2 Method for synthesizing cycloalkanyl[b]indoles, cycloalkanyl[b]benzofurans, cycloalkanyl[b]benzothiophenes, compounds and methods of use TRUSTEES OF DARTMOUTH COLLEGE (US) 2017-03-21 US disclosed
US-20160113937-A1 DISCOVERY OF FDA-APPROVED DRUGS AS INHIBITORS OF FATTY ACID BINDING PROTEIN 4 USING MOLECULAR DOCKING SCREENING THE CHINESE UNIVERSITY OF HONG KONG (CN) 2016-04-28 US disclosed
US-20150057326-A1 Method for Synthesizing Cycloalkanyl[b]indoles, Cycloalkanyl[b]benzofurans, Cycloalkanyl[b]benzothiophenes, Compounds and Methods of Use TRUSTEES OF DARTMOUTH COLLEGE (US) 2015-02-26 US disclosed
US-20140363522-A1 Compositions and Methods for Treating and/or Preventing Cancer by Inhibiting Fatty Acid Binding Proteins NIH - DEITR 2014-12-11 US disclosed
US-8748470-B2 Methods for treating ovarian cancer by inhibiting fatty acid binding proteins THE UNIVERSITY OF CHICAGO (US) 2014-06-10 US disclosed
US-20120289570-A1 COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CANCER BY INHIBITING FATTY ACID BINDING PROTEINS NIH 2012-11-15 US disclosed
WO-2004063156-A1 NOVEL INDOLE DERIVATES AS FABP-4 INHIBITORS BIOVITRUM AB (SE) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230241025-A1 ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS FABP1, FABP4, FABP5 FABP4 2/4885FABP3 4/4885
US-12138243-B2 Antiviral use of FABP4 modulating compounds FABP1, FABP5, FABP4 FABP4 3/4885FABP3 4/4885
US-20150057326-A1 Method for Synthesizing Cycloalkanyl[b]indoles, Cycloalkanyl[b]benzofurans, Cycloalkanyl[b]benzothiophenes, Compounds and Methods of Use CCKBR, GCGR, BDKRB1 FABP4 931/4885FABP3 1320/4885
US-20230255933-A1 ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS FABP1, FABP4, FABP5 FABP4 2/4885FABP3 4/4885
US-20160113937-A1 DISCOVERY OF FDA-APPROVED DRUGS AS INHIBITORS OF FATTY ACID BINDING PROTEIN 4 USING MOLECULAR DOCKING SCREENING FABP4, FABP3, FABP5 FABP4 1/4885FABP3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.